Skip to content

Sutro Biopharma STRO Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-120%+34.5pp-154.5%+21.1pp-175.7%
Net margin-154.2%+32.2pp-186.5%+18.7pp-205.2%
Efficiency
Asset turnover0.4×0.0×0.4×0.0×0.3×0.0×0.3×+0.1×0.2×0.0×
Liquidity
Current ratio3.1×+1.1×-0.5×2.5×-0.6×3.1×+1.0×2.2×-0.4×
Per Share
Book value per share-$5.11+67.2%-$15.59-1,416%-$1.03-171%-$0.38+87.7%-$3.09-154%
Valuation
Market capitalization$489.66M+624%$98.57M+33.9%$73.62M+6.0%$69.46M+27.4%$54.5M-64.1%
Price / sales4.9×+3.9×+0.3×0.7×0.0×0.7×-0.2×0.8×-1.6×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Sutro Biopharma's ratios come from?
Every ratio is computed from Sutro Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.